Orlando, FL/Virtual
On Wednesday, February 5th, Wilson Sonsini partner Eva Yin will participate in a panel hosted by the American Health Law Association. Exploring the topic “Navigating Legal Complexities of AI-Driven SaMD in Health Care,” Eva and co-panelist Akifa Khattak will discuss the FDA and other regulatory considerations for SaMD and unique challenges facing those adopting AI in healthcare spaces. The session will be held in-person and virtually; to register please visit the event website.
Hannah Hebertson
hhebertson@wsgr.com
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.